Prevalence, Trends, and Factors Associated With Antipsychotic Polypharmacy Among Medicaid-Eligible Schizophrenia Patients, 1998–2000

Ganguly, Rahul; Kotzan, Jeffrey A.; Miller, L.S.; Kennedy, Klugh; Martin, Bradley C.

doi:10.4088/jcp.v65n1013

Cited by 210 publications

(208 citation statements)

References 25 publications

Supporting

Mentioning

173

Contrasting

Order By: Relevance

“…Internationally, the rate of polypharmacy in discharged individuals was 28% in Italy, 10 27.5% in Canada, 15 35.6% in Norway 16 and 40% in the Medicaid group in the USA, 17 all higher than what we observed. However, our finding was similar to that of Centorrino et al 18 in the USA and Barbui et al 12 in Italy where 15.8 and 13% respectively were on polypharmacy.…”

Section: 10contrasting

confidence: 77%

Polypharmacy and high-dose antipsychotics at the time of discharge from acute psychiatric wards

2011

View full text Add to dashboard Cite

Aims and methodTo determine the extent of prescribed antipsychotic polypharmacy and high-dose antipsychotics at the time of discharge from an acute psychiatric ward. Copies of discharge summaries for patients between the ages of 18 and 65 were examined; only those that had antipsychotic medications at the time of discharge were included. Names and doses of antipsychotics and all other medications concurrently prescribed were recorded.ResultsA total of 651 discharge summaries were included in the study. Nearly a quarter of individuals were discharged on one antipsychotic as the only medication to take home; only 6.8% were discharged on a high-dose antipsychotic and of those on combinations 59.6% were on depot medications. Combining antipsychotics significantly predicted the use of high dose.Clinical implicationsMost patients were discharged on doses of antipsychotics within the British National Formulary limits; however, a small proportion is still sent home on high doses of antipsychotics. Combining antipsychotics remains the strongest predictor of high-dose antipsychotic use; clinicians need to be aware of this.

show abstract

Section: 10contrasting

confidence: 77%

Polypharmacy and high-dose antipsychotics at the time of discharge from acute psychiatric wards

2011

View full text Add to dashboard Cite

show abstract

“…In a similar survey carried out in the US, looking into only treatment-resistant cases, 33% of cases were on combination therapy comparing to 46.1% in this sample [19]. Although the frequency of antipsychotic polypharmacy was found to vary according to patient, illness, setting and provider variables, rates in schizophrenia commonly were reported to range from 7% to 50% [13,20]. Given that our focus was on resistant cases only, the rate of combination in the present survey is not very far from what was reported in other studies.…”

Section: Discussionmentioning

confidence: 70%

Prescribing trends in treatment-resistant schizophrenia

Görmez

Kurtulmuş

Can

2017

Psychiatry and Clinical Psychopharmacology

View full text Add to dashboard Cite

Objectives: Schizophrenia is a common mental health condition associated with significant morbidity and excess early mortality. Treatment-resistant schizophrenia (TRS) occurs in about one in three patients diagnosed with schizophrenia. The aim of this study was to identify attitudes of a nationally representative sample of psychiatrists towards pharmacotherapy of patients with TRS, the potential factors related to their choice of various regimens, and to investigate the clinical outcomes of different methods employed. Methods: Psychiatrists were contacted through national e-groups and various psychiatry conventions. They provided information about their professional and demographic characteristics. They were asked to describe clinical and demographic characteristics of an adult patient with TRS under their care for at least 3 months. They reported on the medication change they made and the effect of this intervention on the positive symptoms and functioning of the patient. Results: Among the 207 patients reported on, only 28.7% were on monotherapy for TRS immediately before the change in medication. With the change made in treatment regime, 40.1% were switched to a different antipsychotic agent as monotherapy, 40.6% received combination therapy with two or more antipsychotic agents, 1.4% received high-dose antipsychotics, and 4.8% had augmentation with antidepressants or mood stabilizers. 13.1% psychiatrists employed more than one method. Of the whole sample, 48.3% were put on clozapine either as monotherapy or with other medications. The monotherapy and combination groups were compared in terms of characteristics of patients and prescribers, which revealed no significant difference (p > .05). There was also no difference found on the outcome variables of two groups (p > .05). Conclusions: Although polypharmacy was found to be a common practice, there seemed to be a comparably good ratio of clozapine utilization and of attempts of switching to monotherapy among the prescribers. There were no significant patient-or prescriber-related factors in relation to preference of treatment regimens, which need further investigation on larger samples. ARTICLE HISTORY

show abstract

“…79 A well-defined guideline for concomitant use in ADHD children and adolescents can help clinicians. 32,75,80 Mental illness severity has been found to be associated with the use of combination therapy in adults, 63,81 but no such association has been reported in children and adolescents with ADHD. Although the direct relationship between ADHD of commercially insured children and adolescents with ADHD concurrently received LAS and AAPs.…”

Section: Predictors Of Concomitant Use Of Antipsychotics and Stimulanmentioning

confidence: 99%

Predictors of Concomitant Use of Antipsychotics and Stimulants and Its Impact on Stimulant Persistence in Pediatric Attention Deficit Hyperactivity Disorder

Bali

Kamble²,

Aparasu³

2015

JMCP

View full text Add to dashboard Cite

show abstract

Prevalence, Trends, and Factors Associated With Antipsychotic Polypharmacy Among Medicaid-Eligible Schizophrenia Patients, 1998–2000

Cited by 210 publications

References 25 publications

Polypharmacy and high-dose antipsychotics at the time of discharge from acute psychiatric wards

Polypharmacy and high-dose antipsychotics at the time of discharge from acute psychiatric wards

Prescribing trends in treatment-resistant schizophrenia

Predictors of Concomitant Use of Antipsychotics and Stimulants and Its Impact on Stimulant Persistence in Pediatric Attention Deficit Hyperactivity Disorder

Contact Info

Product

Resources

About